GlassScriptPhysician profile
Ella Grace Gift
NPI 1891568358
$5,270.31
in general payments reported to CMS, 2019-2025
24 companies · $3,187 in 2025
The $3,187 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $2,084 · 2025: $3,187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,762 · Education: $508.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,761.83 |
| Education | $508.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $501.69 | 2024-2025 | |
| Abbvie INC. | $477.79 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $455.78 | 2024-2025 | Dupixent |
| Janssen Biotech, INC. | $403.86 | 2024-2025 | Tremfya, Simponi, Simponi Aria |
| Lilly USA, LLC | $361.72 | 2024-2025 | Taltz, Ebglyss, Olumiant |
| Ucb, INC. | $335.36 | 2025 | Bimzelx |
| Amgen INC. | $329.29 | 2024-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $324.30 | 2024-2025 | |
| Organon LLC | $286.44 | 2025 | Vtama |
| Genzyme Corporation | $270.00 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $242.86 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $213.47 | 2024-2025 | Sotyktu |
| Leo Pharma INC. | $183.72 | 2024-2025 | Adbry, Anzupgo |
| Journey Medical Corporation | $178.05 | 2025 | |
| Mayne Pharma Commercial LLC | $133.59 | 2024-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $127.74 | 2024-2025 | Cabtreo, Jublia, Siliq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.47 | 2024-2025 | Spevigo |
| Arcutis Biotherapeutics, INC. | $64.94 | 2024-2025 | Zoryve |
| Incyte Corporation | $63.82 | 2024-2025 | Opzelura |
| Galderma Laboratories, L.P. | $61.98 | 2024-2025 | Nemluvio |
| Almirall LLC | $52.20 | 2025 | Seysara, Klisyri |
| Dermavant Sciences, INC. | $43.49 | 2024 | Vtama |
| Botanix Sb INC | $21.88 | 2025 | Sofdra |
| Paratek Pharmaceuticals, INC. | $15.87 | 2025 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ella Gift listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.